Company: RCUS
Filing Date: 2025-12-12
Form Type: 8-K
Source: 0001724521-25-000120
Chunk: 1

Company: Arcus Biosciences, Inc.
Filing Date: 2025-12-12
Form: 8-K
Item: Item 8.01
Chunk 1
---
 risks associated with preliminary and interim data not being guarantees that future data will be similar; the unexpected emergence of adverse events or other undesirable side effects in the Company’s investigational products, including casdatifan; adverse data from toxicology studies that affect the Company’s ability to advance development candidates from its immunology and inflammation programs, uncertainties in timelines associated with the conduct of clinical studies and with respect to the regulatory approval process; changes in the competitive landscape for the Company’s programs; and the inherent uncertainty associated with pharmaceutical product development and clinical trials. Risks and uncertainties facing the Company are described more fully in the “ Risk Factors” section of Company’s most recent periodic report filed with the U. S. Securities and Exchange Commission (“ SEC”) and in other filings that the Company makes with the SEC from time to time, which are available at www. sec. gov. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company disclaims any obligation or undertaking to update, supplement or revise any forward-looking statements contained in this press release, except to the extent required by law.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

                               ARCUS BIOSCIENCES, INC.                                     
  Date: December 12, 2025      By:                          /s/ Terry Rosen, Ph. D.        
                                                            Terry Rosen, Ph. D.            
                                                            Chief Executive Officer